2023-10-23 12:03:15
How are comorbidities in MS treated?
Awareness and recognition of comorbidities in individuals with multiple sclerosis (MS) is crucial for effective treatment. Without proper diagnosis, treatment options are limited. Unfortunately, many easily treatable diseases often go undetected in people with MS, leading to untreated conditions. Part of this challenge lies in the assumption that every complaint experienced by individuals with MS is attributed solely to the disease itself, without considering alternative explanations.
Recognizing the importance of early detection and treatment, routine measurements of blood pressure, blood lipids, and blood sugar levels are encouraged in individuals with MS, particularly those who are overweight. Additionally, heightened awareness of mental health symptoms among individuals with MS and their doctors is essential for timely intervention. Treatment for comorbidities is based on current scientific knowledge and can be found in medical society guidelines.
Therapies for comorbidities may have positive impacts on MS and its symptoms. However, there can also be negative consequences. For instance, the treatment of high blood pressure with beta-blockers may potentially worsen erectile dysfunction in men with MS. It is important to always consider the impact of MS when treating comorbidities.
On a positive note, certain medications used to manage comorbidities may also have protective effects on disease processes related to MS. Cholesterol-lowering drugs (statins), certain diabetes medications (e.g., metformin or pioglitazone), and certain antidepressants (e.g., fluoxetine) are among the medications that may offer additional benefits in the context of MS. However, it is important to note that these medications cannot replace established MS therapies and should only be seen as potential complements.
Conversely, MS therapies can potentially worsen comorbidities. For example, certain medications such as S1P receptor modulators and teriflunomide may cause an increase in blood pressure during treatment. Regular blood pressure monitoring is recommended for individuals using these medications. Interferon beta preparations, commonly used in MS treatment, have been associated with worsening migraines. Alemtuzumab, another MS therapy, may lead to the development of other autoimmune diseases, including thyroid disease, platelet deficiency, and rarely kidney disease.
In the Quality Manual of the Multiple Sclerosis Competence Network, treating doctors can find comprehensive information on all approved MS medications and strategies to minimize associated risks through appropriate monitoring.
]
#disease #Overview #comorbidities #MedicineTherapy #Multiple #Sclerosis #News